CHANTIX Drug Patent Profile
✉ Email this page to a colleague
When do Chantix patents expire, and what generic alternatives are available?
Chantix is a drug marketed by Pf Prism Cv and is included in one NDA.
The generic ingredient in CHANTIX is varenicline tartrate. There are twelve drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Chantix
A generic version of CHANTIX was approved as varenicline tartrate by ENDO OPERATIONS on August 11th, 2021.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for CHANTIX?
- What are the global sales for CHANTIX?
- What is Average Wholesale Price for CHANTIX?
Summary for CHANTIX
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 98 |
| Clinical Trials: | 167 |
| Patent Applications: | 132 |
| Drug Prices: | Drug price information for CHANTIX |
| Drug Sales Revenues: | Drug sales revenues for CHANTIX |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CHANTIX |
| What excipients (inactive ingredients) are in CHANTIX? | CHANTIX excipients list |
| DailyMed Link: | CHANTIX at DailyMed |
Recent Clinical Trials for CHANTIX
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Massachusetts General Hospital | Phase 3 |
| Mayo Clinic | Early Phase 1 |
| Duke University | Phase 4 |
Pharmacology for CHANTIX
| Drug Class | Cholinergic Receptor Agonist Partial Cholinergic Nicotinic Agonist |
| Mechanism of Action | Cholinergic Agonists Partial Cholinergic Nicotinic Agonists |
Paragraph IV (Patent) Challenges for CHANTIX
| Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
|---|---|---|---|---|---|---|
| CHANTIX | Tablets | varenicline tartrate | 0.5 mg and 1 mg | 021928 | 5 | 2010-05-10 |
US Patents and Regulatory Information for CHANTIX
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-001 | May 10, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Pf Prism Cv | CHANTIX | varenicline tartrate | TABLET;ORAL | 021928-002 | May 10, 2006 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for CHANTIX
See the table below for patents covering CHANTIX around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| African Intellectual Property Organization (OAPI) | 11428 | Aryl fused azapolycyclic compounds. | ⤷ Sign Up |
| South Africa | 200307235 | Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.02,11.04,09]-hexadeca-2(11),3,5,7,9-pentaene. | ⤷ Sign Up |
| Turkey | 200001840 | ⤷ Sign Up | |
| Slovakia | 287170 | ⤷ Sign Up | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CHANTIX
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 1044189 | PA2008010 | Lithuania | ⤷ Sign Up | PRODUCT NAME: VARENICLINUM TARTRAT; REG. NO/DATE: EU/1/06/360/001-010 20060926 |
| 1044189 | SPC/GB08/034 | United Kingdom | ⤷ Sign Up | PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928 |
| 1044189 | 122008000038 | Germany | ⤷ Sign Up | PRODUCT NAME: VARENICLIN GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEHMBAREN SALZES UNTER EINSCHLUSS VON TARTRAT; REGISTRATION NO/DATE: EU/1/06/360/001-010 20060926 |
| 1044189 | CA 2008 00031 | Denmark | ⤷ Sign Up | |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
